Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR)
NCT06130540Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of secukinumab in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) (2 arms), sponsored by Novartis. Primary endpoints: Maximum concentration at steady state at Week 20, Minimum concentration at steady state at Week 20 and 2 more. Started Mar 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT06130540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130540.